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was to identify existing deﬁ nitions of innovation, values inherent in innovation initia-
tives, and important considerations for the development of policies to promote innova-
tion of health technologies. METHODS: A literature search of bibliographic databases 
including PubMed, EMBASE, Web of Science, Centre for Reviews and Dissemination 
databases, National Library of Medicine Gateway, EconLit and the New York 
Academy of Medicine Grey Literature collection was conducted for the period January 
2005 to April 2010. The search terms were intended to capture concepts of “innova-
tion” and “policy” in the health technology (drugs, devices, etc,) sector. Two research-
ers reviewed titles and abstracts of over 4500 references identiﬁ ed; 200 papers were 
retrieved for full review. Key components of innovation were extracted and summa-
rized in tabular form to identify trends and emerging themes. RESULTS: System 
disrupting, development of relationships and improvement on current practice are 
examples of components of, or criteria for deﬁ ning, health technology innovation. 
Thematic concepts that emerged during the review include innovative health technol-
ogy as a novelty and as a mechanism for achieving some beneﬁ t or good (broadly-
deﬁ ned) at various levels of the health system. CONCLUSIONS: Based on the variety 
of deﬁ nitions in the literature, lack of a common understanding of innovation may 
result in policy incoherence. The use of a consistent and unambiguous deﬁ nition 
provides a solid framework from which to develop policy that is measurable, meaning-
ful and, therefore, has a greater chance of being effective.
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OBJECTIVES: Given the signiﬁ cant impact of biomedical technology on health, the 
present study aims at identifying the accessibility to certain biomedical technologies 
and factors affecting its use and diffusion, in Greece. METHODS: A strictly structured 
questionnaire was designed and sent to a sample of 388 internists and GPs over 50 
years old, stratiﬁ ed by geographical area and employment sector. Participants were 
asked a) to evaluate on a 1 to 10 point scale patient access to selected biomedical 
technologies and the degree to which selected factors affect their decision to use the 
above interventions and b) to rank certain factors effect on the diffusion of biomedical 
technologies. RESULTS: The response rate was 76%. The statistical analysis revealed 
that the most accessible biomedical technologies were ultrasonography (9.4), PSA 
(9.38), cardiac enzymes (8.99), MRI and CT (8.86), and mammography (8.83). The 
most important factors affecting participants’ decision to use a technology were the 
treatment outcome (9.23), the disease severity (9.11) and the appropriateness of the 
technology for each condition (8.27) while factors such as health system and patient 
cost were proved less inﬂ uential. 68.1% of participants claimed delays in the diffusion 
of biomedical technology in Greece, identifying as major barriers economic and spe-
cialized human resources deﬁ ciencies. CONCLUSIONS: Based on our results, higher 
access was observed to technologies related to neoplasms and cardiovascular diseases, 
which represent the main causes of morbidity and mortality in Greece. Furthermore, 
our ﬁ ndings support the view that when it comes to use a technology physicians are 
mostly concerned with the clinical effectiveness of an intervention and less with its 
impact on health care expenditures. Finally, the major diffusion barriers identiﬁ ed in 
this study show a suboptimal resource allocation practice, stressing the need for 
measures to be taken in this direction in order to enhance diffusion of biomedical 
technologies in Greece.
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OBJECTIVES: Transparency Directive (TD) of the European Union aims to ensure 
the transparency of procedures for the pricing and reimbursement of medicinal prod-
ucts by Member States. TD proposes strict timelines for the pricing and reimbursement 
process and indicates the necessity of objective and veriﬁ able criteria for decisions and 
the availability of remedies for negative decisions. Our objective was to compare the 
routine process of pharmaceutical pricing and reimbursement with the TD in Hungary. 
METHODS: We analyzed ofﬁ cial resolutions of 29 pricing and reimbursement sub-
missions by the National Health Insurance Fund (NHIF) between January and June 
2008. In 14 cases the NHIF granted reimbursement, in 15 cases the reimbursement 
claim was rejected. We calculated the time period between the submission of the 
reimbursement dossier and the ofﬁ cial decision. We assessed the consistency of apply-
ing objective and veriﬁ able criteria in positive or negative decisions. RESULTS: The 
average time period for pricing and reimbursement procedure was 172 days (min: 43 
days; max: 534 days). We could not justify the consistency of employing objective and 
veriﬁ able criteria in the pricing and reimbursement resolutions of innovative pharma-
ceuticals. CONCLUSIONS: The pharmaceutical pricing and reimbursement process 
in Hungary is neither transparent nor predictable. There are several open pricing and 
reimbursement submissions without resolution for long period. Although we could 
analyze only cases with resolution, the time period for pricing and reimbursment 
decision was still longer in several cases than 90 + 90 days recommended by TD. The 
appropriate use of scarce public health care resources could not be justiﬁ ed in case of 
positive decisions and there is no remedy for negative reimbursement decisions. TD 
has been implemented only partially in Hungary.
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OBJECTIVES: The Joint Committee for New Drugs Evaluation (JCNDE) was estab-
lished in 2003 to improve efﬁ ciency in drug evaluation in Spain. Five Regional Drug 
Evaluation Centres are part of it and have common Standard Operating Procedures 
(SOPs) which are regularly updated and improved. The objective of this study was to 
analyze the drugs innovation degree scores assigned by the JCNDE and timing between 
the new drug commercialization and the JCNDE evaluation. METHODS: The JCNDE 
SOPs deﬁ ne a stepwise procedure with 4 key criteria for new drug innovation ratings: 
efﬁ cacy, safety, convenience and drug cost. The drug innovation scores range from 0 
(insufﬁ cient experience with the drug) to 4 (relevant therapeutic improvement). The 
drug evaluation results were gathered from JCNDE reports and from the Regional 
Drug evaluation centre reports. The time period analyzed was from 2004 to 2009. 
RESULTS: Ninety drug evaluations were held, considering 86 different drugs and 11 
evaluations for a new drug indication for the same drug. Seventy-eight (87%) of the 
evaluations were negative (scores 0–1), not ﬁ nding any 0 in the last 2 years of the 
study. Ten and 2 evaluations were scored as 2 and 3 respectively. None of the drugs 
assessed were considered a relevant therapeutic improvement compared to the existing 
options. Five drugs not reimbursed were evaluated. Median time since commercializa-
tion to evaluation was 6 months (IQR: 2–11 months) and 32 drug evaluations were 
held before up to a maximum of 3 months after commercialization. CONCLUSIONS: 
The JCNDE has been an efﬁ cient instrument to develop new drug assessments in the 
Primary Care setting for the Regional Health Systems in Spain. Most of the assess-
ments held have been negative. At present, health-economics arguments are basically 
focused on the daily treatment cost comparisons. About 1/3 of the evaluations are 
started before drug commercialization.
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OBJECTIVES: The Spanish Joint Committee for New Drugs Evaluation (JCNDE) was 
created in 2003 and is formed by 5 Regional Drug Evaluation Centres. JCNDE has 
common Standard Operating Procedures (SOPs) to unify drug assessments and where 
the comparators availability is a key issue. Each individual Drug Evaluation Centre 
has its own new drug therapeutic bulletin to spread information between their health 
professionals. The objective of this study was to quantify the uniformity degree 
through the drug bulletins and the degree of heterogeneity reﬂ ected in the drug costs. 
METHODS: New drug therapeutic bulletins of the 5 members of the JCNDE were 
reviewed between 2006 and 2009. Each drug assessed by the JCNDE was tracked to 
identify which members reported it in their bulletins. Comparative drugs included in 
the bulletins were also registered to ﬁ nd potential heterogeneity amongst the JCNDE 
members. Daily/monthly treatment costs described were included in the study data-
base. RESULTS: Fifty-seven drug evaluations were recorded, forty (70%) were pub-
lished by at least 3 members of the JCNDE, and only 12 were published by all of 
them. Andalusia, Basque Country and Catalonia are the most active members, with 
12–14 new drugs published per year. In all the bulletins were identiﬁ ed some differ-
ences in the comparators used for each new drug assessed. Andalusia and Catalonia 
tend to include more comparators. The highest level of heterogeneity is observed in 
drugs of diabetes treatment. Most of the drug costs reported were very similar. Only 
one disagrement between the JCNDE was identiﬁ ed in the drug innovation rating. 
CONCLUSIONS: JCNDE has made advances to unify drug assessment in Spain. 
Nevertheless, health-economics arguments are still focused on drug treatment cost 
comparisons. The comparators found in the drug bulletins are slightly different 
amongst the regions. Future SOPs version ought to improve these two weak points.
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OBJECTIVES: To promote the research and development of drugs for rare diseases, 
like other countries, orphan designations have been granted to pharmaceuticals in 
Japan since 1993. We investigated the accessibility of orphan drugs in Japan by 
comparing the accessibility of orphan designated and marketing authorised drugs in 
the EU and the US. METHODS: The present study used the data available until the 
November 30, 2009 from the European Medicines Agency, US Food and Drug 
Administration and National Institute of Biomedical Innovation. The International 
Nonproprietary Names (INNs) were used for comparing authorised orphan desig-
nated drugs in Japan, the EU and the US. RESULTS: A total of 228 products had 
been granted orphan designation, of which 142 (62%) obtained marketing authoriza-
tion in Japan, which is equivalent to 122 in INNs. Meanwhile, the number of autho-
rised orphan-designated medicines in INNs in the EU and the US was 57 and 198, 
respectively. Of the total 287 authorised orphan-designated pharmaceuticals in INNs 
in these 3 regions, 165 were inaccessible in Japan through the orphan designation 
system. Among such drugs, 25 (15%) were authorised orphan designated in both the 
EU and the US, 15 (9%) were authorised orphan designated in the EU alone and 125 
(76%) were authorised orphan designated in the US alone. CONCLUSIONS: We 
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observed that the orphan designation system in Japan has achieved certain results for 
increasing the accessibility of necessary drugs to patients suffering with rare diseases. 
However, several drugs are still not available in Japan, partly because of the difference 
in deﬁ nitions of orphan disease among the 3 regions. To increase the accessibility to 
orphan drugs, further policy interventions should be considered.
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OBJECTIVES: There is a continuous problem in Hungary—and assumable in many 
other countries—with planning the health insurance pharmaceutical budget. In 
Hungary there is a substantial gap between the planned and the actual budget resulting 
in an overspending of the planned pharmaceutical budget. The aim of our study is to 
analyze the gap between the planned and the actual health insurance pharmaceutical 
budget. METHODS: Data were derived from the nationwide administrative data set 
of the National Health Insurance Fund Administration (OEP), the only health care 
ﬁ nancing agency in Hungary. We analyzed the difference between the planned and 
the actual pharmaceutical budget of OEP between 1994 and 2006. Outcome (over-
spending rate) is measured with the following formula: the difference between the 
planned and the actual budget is divided with the planned budget. RESULTS: During 
the period of 1994–2006 we found signiﬁ cant overspending of pharmaceutical budget 
of OEP which varied between 3.4–36.6% of actual pharmaceutical expenditures. The 
peak of overspending showed a 4 years circle with the highest ﬁ gures in 1994 (21,5%), 
1998 (32.1%), 2002 (36.6%) and 2006 (30.4%). These 4 calendar years correspond 
with the time of national political (parliamentary) elections. CONCLUSIONS: We 
found the highest overspending of the Hungarian pharmaceutical budget in the years 
of national political elections. It is a scientiﬁ c evidence for the political inﬂ uence of 
the health insurance pharmaceutical budget. The overspending does not relate to any 
speciﬁ c political parties or governments because it was a general phenomenon in 
Hungary between 1994–2006.
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BACKGROUND: The Greek economy is being called upon to manage one of the 
highest proportions of public debt versus GDP in the European Union and the Euro 
zone. In turn, the health care sector is subject to the distortions of the Greek public 
sector, as there is no ofﬁ cial method of measuring and evaluating the services being 
provided. OBJECTIVES: The objective of this analysis was both to interpret the 
development of pharmaceutical expenditure, based on the most signiﬁ cant changes in 
the pricing and reimbursement system, as well as to evaluate the institutional changes 
based on their effectiveness. METHODS: The analysis reﬂ ects the evolution of phar-
maceutical expenditure and interprets the changes in the regulatory framework that 
took place in Greece from 1998–2008. It should be noted that there is signiﬁ cant 
confusion around the actual level of pharmaceutical expenditure, as the data provided 
for 2003–2007 (provisional data) from the National Statistical Service of Greece are 
not in agreement with OECD’s data. Following a more careful analysis of the data, 
numerous questions arise with respect to their reliability, as there is no explanation 
for the apparent rate of change with regard to the factors that could inﬂ uence expen-
diture (e.g. changes in the pricing or reimbursement system). Therefore the actual level 
of pharmaceutical expenditure is also in question. RESULTS: After analyzing the price 
changes in the top 100 selling pharmaceutical products in Greece, throughout the 
indicated period, it became obvious that the cause of increasing pharmaceutical 
expenditure cannot be attributed to increasing prices, but to other factors mainly 
associated with over-consumption. CONCLUSIONS: Finally, taking into account the 
intense pressures on public ﬁ nancing of the health care system, it is important for any 
future measures to constrain costs to be based on reliable and accurate data and to 
target the entirety of the system.
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OBJECTIVES: The Slovak guidelines for economic evaluation, although appearing to 
be generic, have been written focusing on pharmaceuticals. The objective of this study 
was to analyze the quality of submitted economic studies and related critical appraisals 
process and to develop a policy-relevant, publicly available Slovak critical appraisal 
checklist for improving the quality of economic evaluation for reimbursement submis-
sion of dossiers concerning to medical devices. METHODS: We created a working 
group to review previously submitted economic evaluations and related critical 
appraisals in order to identify potential technical and methodological problems. The 
working group consisted of two independent academic experts who scrutinized previ-
ous submissions and critical appraisals concerning to medical devices between 2007–
2010. RESULTS: Evidence suggests that the methods of economic evaluation can be 
equally applied to drugs and devices in general. However, there are several speciﬁ c 
methodological issues that require more attention if reliable and informative evalua-
tions of devices are to be conducted. These issues are underestimated within the Slovak 
Republic. It is well known that expenditures for medical devices do not result in the 
most cost-effective outcomes. Economic evaluations of medical devices are mandatory 
but the quality of evaluations and critical appraisals are poor. Our analysis shows that 
the simpliﬁ ed questionnaire, which is currently used for the critical appraisal process 
within Slovakia should be replaced by a new Slovak critical appraisal checklist, which 
will be detailed enough to address the speciﬁ c problems in the local economic evalu-
ations process. CONCLUSIONS: The transparent method of technology assessment 
can improve the consistency of reimbursement decisions making related to medical 
devices in Slovakia. Therefore in addition to the available Slovak health economic 
evaluation guidelines a detailed checklist for appraisal processes speciﬁ c for medical 
devices have to be prepared. The economic evaluation of devices raises additional 
challenges and the current Slovak guidelines overlook several issues.
PHP21
EARLY ACCESS: ANALYSIS OF THE FRENCH ATU SYSTEM
Hensen M1, Heemstra HE1, Meijboom MJ1, Doreau C2
1Pharmerit International, Rotterdam, The Netherlands; 2Consultant, Antibes, France
OBJECTIVES: The French cohort ATU provides early access to medicines for serious 
or rare diseases prior to marketing authorization (MA) for groups of patients. This 
study determines the length of time of patient access before MA for different types 
and classes of products subject to a cohort ATU. METHODS: All medicines subject 
to a cohort ATU between 1994 and 2009 were obtained from the website of Afssaps. 
Products which were never authorized were excluded. Time from initiation of a cohort 
ATU to marketing authorization was determined. Subgroup analyses were performed 
for orphan products, products developed by small and medium enterprises (SMEs), 
and products in major indication classes. RESULTS: 87 products matched the inclu-
sion criteria. Products were available on average 23 (range 0–121) months prior to 
MA. Orphan drugs (N = 13;15%) and non-orphan drugs were available 19 months 
(2–74) and 24 (0–121) months before MA respectively. Drugs developed by SMEs (N 
= 5;6%) were available on average 34 (9–59) months before MA, while drugs devel-
oped by larger companies were available 22 (0–121) months before MA. Blood 
products (ATC = B;N = 10;11%) were available on average 53 (2–121) months before 
MA, and anti-infectives (ATC = J;N = 31;36%) 15 (0–70) months, followed by 13 
(1–74) months for oncology products (ATC = L;N = 19;21%). The average length of 
time before MA decreased from 21.4 between 1994 and 2003 to 3.7 between 2004 
and 2008. CONCLUSIONS: This study demonstrates that the cohort ATU provides 
access to medicines several months before MA and has been used primarily by larger 
pharmaceutical companies. The length of time of access before MA differs by indica-
tion and type of product and has been shorter in recent years. Price level and indication 
should reﬂ ect future authorized indications and price. The lower than expected 
number of orphan drugs subject to a cohort ATU may be the result of more frequent 
use via the nominative ATU or in clinical trials.
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OBJECTIVES: To gather insights into global (5EU, US, emerging markets) national 
policy & key decision-makers’ beliefs & perceptions on current and future landscape 
as well as impact and value of telehealth/telemedicine initiatives within health care 
programmes from health economic perspectives. METHODS: Both primary and sec-
ondary research was used for this study. Literature reviews with compilation of all 
relevant and up-to-date information including data in local languages. Primary 
research focused on market speciﬁ cs where clariﬁ cation and market insights were 
required (such as MOH, budget-holder’s organizations, Public Health Institutions, 
senior health care professionals). RESULTS: Beneﬁ ts for improving both accessibility 
and quality of health care through telehealth/telemedicine have vast potential. These 
initiatives require substantial investment, whereas human and ﬁ nancial resources are 
limited. It is important to demonstrate economic viability, in addition to technical and 
clinical evaluations, in order to understand the optimal conditions under which new 
telehealth/telemedicine programmes should be unfolded. Traditionally, cost-effective-
ness analysis is used to evaluate telehealth/telemedicine programmes. Such an approach 
is represented only by monetary differentials (ﬁ xed, variable, marginal, and direct and 
indirect costs) and has numerous limitations due to the lack of available data as well 
as constant changes in technological progress. As discovered, it is imperative to add 
a range of different analytical techniques to traditional cost analyses. Other factors—
such as perception and investment choices, quality of health care provision, consumer 
choice and political environment—should be taken into consideration. CONCLU-
SIONS: To understand the criteria national leaders use, and the supporting evidence 
they require, to allocate monetary resources for innovative telehealth/telemedicine 
programmes—traditional monetary analysis is not enough and we recommend two 
supplementary approaches: societal and perceptual analysis. This will allow further 
insights on views and value that telehealth/telemedicine initiatives deliver—and the 
priority within health care programmes—in order to reveal the willingness to pay 
among key decision-makers.
